Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:BTMD - US0906831039 - Common Stock

2.53 USD
-0.09 (-3.44%)
Last: 11/24/2025, 8:00:02 PM
2.53 USD
0 (0%)
After Hours: 11/24/2025, 8:00:02 PM

BTMD Key Statistics, Chart & Performance

Key Statistics
Market Cap125.08M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Shares49.44M
Float28.97M
52 Week High6.98
52 Week Low2.32
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.87
PE2.91
Fwd PE7.37
Earnings (Next)03-10 2026-03-10/amc
IPO2021-03-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


BTMD short term performance overview.The bars show the price performance of BTMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20 -25

BTMD long term performance overview.The bars show the price performance of BTMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of BTMD is 2.53 USD. In the past month the price decreased by -12.76%. In the past year, price decreased by -61.72%.

BIOTE CORP -A / BTMD Daily stock chart

BTMD Latest News, Press Relases and Analysis

BTMD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.67 1.01T
JNJ JOHNSON & JOHNSON 19.85 496.24B
MRK MERCK & CO. INC. 11.4 250.78B
PFE PFIZER INC 7.88 143.39B
BMY BRISTOL-MYERS SQUIBB CO 7.28 97.21B
ZTS ZOETIS INC 19.38 54.45B
RPRX ROYALTY PHARMA PLC- CL A 9.67 23.18B
VTRS VIATRIS INC 4.54 12.32B
ELAN ELANCO ANIMAL HEALTH INC 24.05 11.47B
CORT CORCEPT THERAPEUTICS INC 88.31 8.17B
AXSM AXSOME THERAPEUTICS INC N/A 7.54B
BLTE BELITE BIO INC - ADR N/A 4.75B

About BTMD

Company Profile

BTMD logo image biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Company Info

BIOTE CORP -A

1875 W. Walnut Hill Ln #100, Floor 5

Irving TEXAS US

Employees: 217

BTMD Company Website

BTMD Investor Relations

Phone: 19724869346

BIOTE CORP -A / BTMD FAQ

Can you describe the business of BIOTE CORP -A?

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.


What is the stock price of BIOTE CORP -A today?

The current stock price of BTMD is 2.53 USD. The price decreased by -3.44% in the last trading session.


What is the dividend status of BIOTE CORP -A?

BTMD does not pay a dividend.


What is the ChartMill rating of BIOTE CORP -A stock?

BTMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


On which exchange is BTMD stock listed?

BTMD stock is listed on the Nasdaq exchange.


How is the valuation of BIOTE CORP -A (BTMD) based on its PE ratio?

The PE ratio for BIOTE CORP -A (BTMD) is 2.91. This is based on the reported non-GAAP earnings per share of 0.87 and the current share price of 2.53 USD.


Can you provide the short interest for BTMD stock?

The outstanding short interest for BIOTE CORP -A (BTMD) is 3.35% of its float.


BTMD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BTMD Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BTMD. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BTMD Financial Highlights

Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS increased by 190% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.72%
ROA 25.87%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-33.33%
Sales Q2Q%-6.67%
EPS 1Y (TTM)190%
Revenue 1Y (TTM)-18.44%

BTMD Forecast & Estimates

11 analysts have analysed BTMD and the average price target is 5.2 USD. This implies a price increase of 105.34% is expected in the next year compared to the current price of 2.53.

For the next year, analysts expect an EPS growth of 166.59% and a revenue growth -2.93% for BTMD


Analysts
Analysts81.82
Price Target5.2 (105.53%)
EPS Next Y166.59%
Revenue Next Year-2.93%

BTMD Ownership

Ownership
Inst Owners64.32%
Ins Owners9.75%
Short Float %3.35%
Short Ratio7.87